NEW YORK (GenomeWeb News) – Exagen Diagnostics, which develops genomic tests aimed at rheumatology, announced on Monday the completion of a financing round that raised $5.3 million.

The funding will be used to expand the market for the Albuquerque, NM-based firm's brands and further development of near-term pipeline products, it said. Exagen plans to expand its three marketed rheumatology brands — Avise SLE, Avise PG, and Avise MCV — and other products that will help physicians diagnose and treat rheumatologic disorders, company President and CEO Ron Rocca said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.